Breaking News, Collaborations & Alliances

RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt

Production will take place in Minapharm’s biotech facility in Cairo for global distribution.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG have entered an agreement to produce over 40 million doses per year of the Sputnik V COVID-19 vaccine.   The parties intend to commence technology transfer immediately. The rollout of the vaccine is expected in 3Q 2021.   RDIF and Minapharm will initially supply over 40 million doses per year. Production will...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters